A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma

Leukemia

Volumn 28, Issue 5, 2014, Pages 1092-1102

  Horvilleur, E ^a   Sbarrato, T ^a   Hill, K ^a,e   Spriggs, R V ^a   Screen, M ^a   Goodrem, P J ^a   Sawicka, K ^a,f   Chaplin, L C ^a   Touriol, C ^b   Packham, G ^c   Potter, K N ^c   Dirnhofer, S ^d   Tzankov, A ^d   Dyer, M J S ^a   Bushell, M ^a   MacFarlane, M ^a   Willis, A E ^a  

^a MRC TOXICOLOGY UNIT   (United Kingdom)

^b INSERM   (France)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e BABRAHAM INSTITUTE   (United Kingdom)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

apoptosis; DNA repair; eIF4B; lymphoma; microarray analysis; mTOR

Indexed keywords

2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; AZD 8055; DAXX PROTEIN; ERCC5 PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; INITIATION FACTOR 2ALPHA; INITIATION FACTOR 4A; INITIATION FACTOR 4B; INITIATION FACTOR 4E; INITIATION FACTOR 4G; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN BCL 2; PROTEIN KINASE B; RNA HELICASE; TUBULIN; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; MICROARRAY ANALYSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; UPREGULATION;

5' UNTRANSLATED REGIONS; CELL LINE, TUMOR; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EUKARYOTIC INITIATION FACTORS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UP-REGULATION;

EID: 84899944860     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.295     Document Type: Article

References (50)

1. Stoneley M, Willis AE. Aberrant regulation of translation initiation in tumorigenesis. Curr Mol Med 2003; 3: 597-603.
2. Braunstein S, Karpisheva K, Pola C, Goldberg J, Hochman T, Yee H. et al. A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol Cell 2007; 28: 501-512.
3. Le Quesne JP, Spriggs KA, Bushell M, Willis AE. Dysregulation of protein synthesis and disease. J Pathol 2010; 220: 140-151.
4. Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: Mechanisms and biological targets. Cell 2009; 136: 731-745.
5. Bushell M, Wood W, Carpenter G, Pain VM, Morley SJ, Clemens MJ. Disruption of the interaction of mammalian protein synthesis eukaryotic initiation factor 4B with the poly(A)-binding protein by caspase-And viral protease-mediated cleavages. J Biol Chem 2001; 276: 23922-23928.
6. Parsyan A, Svitkin Y, Shahbazian D, Gkogkas C, Lasko P, Merrick WC. et al. mRNA helicases: The tacticians of translational control. Nat Rev Mol Cell Biol 2011; 12: 235-245.
7. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, Sonenberg N. eIF4E-from translation to transformation. Oncogene 2004; 23: 3172-3179.
8. Averous J, Proud CG. When translation meets transformation: The mTOR story. Oncogene 2006; 25: 6423-6435.
9. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-511.
10. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V. et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005; 106: 3183-3190.
11. Huang JZ, Sanger WG, Greiner TC, Staudt LM, Weisenburger DD, Pickering DL. et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002; 99: 2285-2290.
12. Rosenwald A, Staudt LM. Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma 2003; 44(Suppl 3): S41-S47.
13. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI. et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947.
14. Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L. et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102: 3871-3879.
15. Friedberg JW. New strategies in diffuse large B-cell lymphoma: Translating findings from gene expression analyses into clinical practice. Clin Cancer Res 2011; 17: 6112-6117.
16. Schwanhaeusser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J. et al. Global quantification of mammalian gene expression control. Nature 2011; 473: 337-342.
17. Li JJ, Bickel PJ, Biggin MD. System wide analyses have underestimated protein abundances and transcriptional importance in mammals. arXiv.org eprint archive, arXiv:1212.0587v6.
18. Clemens MJ, Bushell M, Morley SJ. Degradation of eukaryotic polypeptide chain initiation factor (eIF) 4G in response to induction of apoptosis in human lymphoma cell lines. Oncogene 1998; 17: 2921-2931.
19. West MJ, Stoneley M, Willis AE. Translational induction of the c-myc oncogene via activation of the FRAP/TOR signalling pathway. Oncogene 1998; 17: 769-780.
20. Johannes G, Carter MS, Eisen MB, Brown PO, Sarnow P. Identification of eukaryotic mRNAs that are translated at reduced cap binding complex eIF4F concentrations using a cDNA microarray. Proc Natl Acad Sci USA 1999; 96: 13118-13123.
21. Horvilleur E, Bauer M, Goldschneider D, Mergui X, de la Motte A, Benard J. et al. p73alpha isoforms drive opposite transcriptional and post-Transcriptional regulation of MYCN expression in neuroblastoma cells. Nucleic Acids Res 2008; 36: 4222-4232.
22. Smyth GK, Michaud J, Scott HS. Use of within-Array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 2005; 21: 2067-2075.
23. Smyth GK, Speed T. Normalization of cDNA microarray data. Methods 2003; 31: 265-273.
24. Breitling R, Armengaud P, Amtmann A, Herzyk P. Rank products: A simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett 2004; 573: 83-92.
25. Hong F, Breitling R, McEntee CW, Wittner BS, Nemhauser JL, Chory J. RankProd: A bioconductor package for detecting differentially expressed genes in meta-Analysis. Bioinformatics 2006; 22: 2825-2827.
26. Obermann EC, Went P, Zimpfer A, Tzankov A, Wild PJ, Stoehr R. et al. Expression of minichromosome maintenance protein 2 as a marker for proliferation and prognosis in diffuse large B-cell lymphoma: A tissue microarray and clinicopathological analysis. BMC Cancer 2005; 5: 162.
27. Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 1987; 8: 138-140.
28. Therneau TM, Li H. Computing the Cox model for case cohort designs. Lifetime Data Anal 1999; 5: 99-112.
29. Lorenz WA, Clote P. Computing the partition function for kinetically trapped RNA secondary structures. PLoS One 2011; 6: E16178.
30. Kramer MH, Hermans J, Parker J, Krol AD, Kluin-Nelemans JC, Haak HL. et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: A population-based study. J Clin Oncol 1996; 14: 2131-2138.
31. Pichon X, Wilson LA, Stoneley M, Bastide A, King HA, Somers J. et al. RNA binding protein/RNA element interactions and the control of translation. Curr Protein Pept Sci 2012; 13: 294-304.
32. Park EH, Zhang F, Warringer J, Sunnerhagen P, Hinnebusch AG. Depletion of eIF4G from yeast cells narrows the range of translational efficiencies genomewide. BMC Genomics 2011; 12: 68.
33. Blagden SP, Willis AE. The biological and therapeutic relevance of mRNA translation in cancer. Nat Rev Clin Oncol 2011; 8: 280-291.
34. Rogers Jr. GW, Richter NJ, Lima WF, Merrick WC. Modulation of the helicase activity of eIF4A by eIF4B, eIF4H, and eIF4F. J Biol Chem 2001; 276: 30914-30922.
35. Shahbazian D, Parsyan A, Petroulakis E, Topisirovic I, Martineau Y, Gibbs BF. et al. Control of cell survival and proliferation by mammalian eukaryotic initiation factor 4B. Mol Cell Biol 2010; 30: 1478-1485.
36. Sebestyen A, Sticz TB, Mark A, Hajdu M, Timar B, Nemes K. et al. Activity and complexes of mTOR in diffuse large B-cell lymphomas-A tissue microarray study. Mod Pathol 2012; 25: 1623-1628.
37. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A. et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012; 485: 55-61.
38. Thoreen CC, Chantranupong L, Keys HR, Wang T, Gray NS, Sabatini DM. A unifying model for mTORC1-mediated regulation of mRNA translation. Nature 2012; 485: 109-113.
39. Tsujimoto Y, Bashir MM, Givol I, Cossman J, Jaffe E, Croce CM. DNA rearrangements in human follicular lymphoma can involve the 5? or the 3? region of the bcl-2 gene. Proc Natl Acad Sci USA 1987; 84: 1329-1331.
40. Buggins AG, Pepper CJ. The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. Leuk Res 2010; 34: 837-842.
41. Barrans SL, Carter I, Owen RG, Davies FE, Patmore RD, Haynes AP. et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99: 1136-1143.
42. Perlman R, Schiemann WP, Brooks MW, Lodish HF, Weinberg RA. TGF-betainduced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation. Nat Cell Biol 2001; 3: 708-714.
43. Yang X, Khosravi-Far R, Chang HY, Baltimore D. Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell 1997; 89: 1067-1076.
44. Chen LY, Chen JD. Daxx silencing sensitizes cells to multiple apoptotic pathways. Mol Cell Biol 2003; 23: 7108-7121.
45. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A. et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011; 331: 1199-1203.
46. Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, van Krieken JH. et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998; 92: 3152-3162.
47. Dunleavy K, Wilson WH. Differential role of BCL2 in molecular subtypes of diffuse large B-cell lymphoma. Clin Cancer Res 2011; 17: 7505-7507.
48. Lord CJ, Ashworth A. Bringing DNA repair in tumors into focus. Clin Cancer Res 2009; 15: 3241-3243.
49. Kim HK, Choi IJ, Kim CG, Kim HS, Oshima A, Michalowski A. et al. A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients. PLoS One 2011; 6: E16694.
50. Witzens-Harig M, Memmer ML, Dreyling M, Hess G. A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma-The STORM trial. BMC Cancer 2013; 13: 308.